ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

What Rheumatologists Should Know About B Cell Tolerance & Autoimmunity

Katie Robinson  |  Issue: October 2025  |  October 8, 2025

Case Presentation 

The case presentation follows a 27-year-old male patient with end-stage renal disease secondary to X-linked Alport syndrome. After three years on hemodialysis, he received a deceased donor kidney transplant. Post-transplant, the patient initially presented with stable creatinine levels of around 1.2 mg/dL. At 10 months post-transplant, he developed an acute onset of hematuria, proteinuria and rapidly deteriorating allograft function, with a creatinine level rising to 4.6 mg/dL over one week. 

Dysmorphic red blood cells (RBCs) and RBC casts were detected by urinalysis. Allograft biopsy revealed linear deposition of immunoglobulin G along the GBM. Crescent formation presented in 60% of the glomeruli along with high titer circulating anti-GBM antibodies. 

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The findings confirmed the diagnosis of de novo anti-GBM disease in a kidney allograft, but the rheumatology team mulled the immunopathology of the case.

“The development of two rare, and seemingly unrelated, kidney diseases in one patient raises interesting questions pertinent to the pathogenesis of humoral autoimmunity,” write Dr. Jackson and Dr. Ponnan. 

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Layered Checkpoints in B Cell Tolerance

Central tolerance eliminates most highly autoreactive B cells, but B cell tolerance is maintained in the periphery. 

Central tolerance occurs in the bone marrow. It comprises clonal deletion of high-affinity self-reactive B cells and receptor editing of these cells to modify B cell receptor binding. During peripheral tolerance, self-reactive mature B cells become functionally unresponsive to antigens. These anergic B cells also show a reduced ability to access B cell follicles in secondary lymphoid organs and have short lifespans.

“These anergic B cells could potentially become activated and enter a germinal center response if they successfully acquire T cell help,” the authors explain. “For this reason, a key peripheral tolerance checkpoint limits the recruitment of self-reactive B cells into germinal centers during initial cognate interactions between T helpers and B cells.”

During germinal center tolerance, de novo autoreactive B cells generated by somatic hypermutation are deleted. B cell tolerance is also regulated by T cells via the central deletion of potential B cell helpers and the control of germinal center responses, influenced by the balance of T follicular helper and regulatory cells. 

Despite the potential for autoreactive B cells to escape inhibitory control, the immune system maintains cells with low self-antigen affinity in a functional anergy state. The authors explain the reason for this is that “many pathogens express surface epitopes that mimic self-antigens,” so “a repertoire entirely devoid of self-reactivity would leave ‘gaps’ in immune coverage rendering individuals vulnerable to invasive pathogens.”

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsOther Rheumatic ConditionsResearch Rheum Tagged with:Alport syndromeanti-GBM diseaseautoantibodiesautoreactive B cellsB cell toleranceB cellsGlomerulonephritiskidney diseaseneoantigensT-cells

Related Articles

    Is B a Key to Autoimmune Therapy?: B Cell-Targeted Therapies in Autoimmune Disease

    January 1, 2010

    A perspective on B cell–targeted therapies in autoimmune disease

    Cellular Therapy of Autoimmune Disease

    November 1, 2008

    Is a novel treatment breakthrough on the horizon?

    How a Nuclear Molecule Alarms the Immune System

    August 1, 2011

    The role of HMGB1 in the pathogenesis of lupus nephritis

    T Cells in Systemic Lupus Erythematosus

    August 1, 2011

    Progress toward targeted therapy

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences